CBCT在线每日自适应放疗改善前列腺癌SBRT靶区覆盖但对OAR保护获益有限
该研究回顾性分析了30例接受CBCT在线自适应SBRT的前列腺癌患者,分低剂量组(30 Gy前列腺及精囊+35 Gy前列腺推量)和高剂量组(30 Gy+37.5 Gy推量),每分次比较计划方案与自适应方案的靶区覆盖和OAR剂量。结果显示自适应计划显著改善靶区覆盖(p<0.001),但OAR剂量获益不一致,高处方剂量组OAR剂量更高。
要点
- CBCT在线自适应SBRT显著改善前列腺癌靶区覆盖(p<0.001)。
- OAR剂量获益不一致,部分OAR体积在自适应计划中反而变差。
- 高处方剂量组OAR剂量更高,但靶区覆盖改善幅度与低剂量组相似。
核心结论
- CBCT在线自适应SBRT较计划方案显著改善前列腺癌靶区覆盖,OAR剂量获益因结构而异,高处方剂量下自适应计划的剂量学优势更明显。
研究设计与样本
- 回顾性分析30例接受CBCT在线自适应同步推量SBRT的前列腺癌患者,分5次治疗,分为低剂量组和高剂量组。
- 每分次生成计划方案(SCH)和自适应计划(ADP),收集8个靶区体积参数和15个OAR的DVH参数进行比较。
主要发现
- ADP计划在两组及整体队列中靶区覆盖均显著改善(p<0.001),SCH计划常未达到PTV前列腺目标。
- 整体队列中ADP有7个OAR体积参数显著变差,OAR剂量降低不一致。
- 亚组分析中膀胱、直肠、乙状结肠、股骨和阴茎球参数存在显著差异。
- 低剂量组ADP的直肠D0.04cm3和直肠D50%略高于SCH。
- 高剂量组ADP的直肠D0.04cm3、直肠D1cm3、膀胱壁V18.3 Gy、膀胱D40%显著降低,膀胱V37Gy、膀胱壁D15cm3、阴茎球D5cm3、阴茎球D3cm3、乙状结肠D20cm3升高。
关键数值与推荐
- 低剂量组处方:精囊和前列腺30 Gy,前列腺35 Gy。
- 高剂量组处方:精囊和前列腺30 Gy,前列腺推量37.5 Gy。
- 靶区覆盖改善在低剂量组和高剂量组相似,但更高处方剂量与SCH和ADP计划中OAR剂量增加相关,尤其在高剂量组。
临床怎么用
- 支持将在线自适应放疗整合入前列腺癌SBRT以优化疗效和安全性。
- 自适应计划应关注OAR剂量可能变差的情况,尤其在高处方剂量组需个体化评估。
局限性
- 回顾性研究,样本量30例。
- OAR剂量获益不一致,部分OAR参数在自适应计划中变差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The precise application of stereotactic body radiation therapy (SBRT) for prostate cancer is challenged by prostate motion and anatomical variations in surrounding organs such as the bladder and rectum. Online adaptive radiotherapy (oART) using cone beam computed tomography (CBCT) has been shown to improve target coverage while limiting doses to organs-at-risk (OARs). METHODS: We retrospectively analyzed data from 30 prostate cancer patients who were treated with CBCT-based oART simultaneous integrated boost SBRT in five fractions, divided into two dose groups: lower dose group (LDG) receiving 30 Gy to seminal vesicles and prostate, and 35 Gy to prostate, and higher dose group (HDG) receiving 30 Gy to the vesicles and prostate, and 37.5 Gy boost to the prostate. Target volumes and OARs were contoured and evaluated per fraction. For each fraction, SCH (Scheduled plan) and ADP (Adaptive plan) plans were generated. Eight target volumes and fifteen OAR DVH (Dose Volume Histogram) parameters were collected and analyzed. Statistical comparisons were performed between differences in target coverages and doses to OARs in SCH and ADP plans, and between the LDG and HDG groups. RESULTS: Target coverages were significantly improved in ADP plans in both cohorts and across the entire cohort (p < 0.001). SCH plans often failed to achieve the goal for PTV prostate. The median differences between target volume parameters of SCH and ADP plans were consistent, the adaptive plans were always superior regardless of the prescribed dose. Significant deterioration in ADP was found across the entire cohort in 7 OAR volumes. Dose reductions in OARs due to adaptation were less consistent. Significant differences were observed in bladder, rectum, sigmoid, femur, and penile bulb parameters in the sub-group analysis. The LDG-ADP plans resulted in slightly higher values of rectumD0.04cm3 and rectumD50% than LDG-SCH, whereas in the HDG-ADP plans significantly lower doses for the rectum D0.04cm3, rectumD1cm3, bladder wallV18.3 Gy, bladderD40% and higher value for bladderV37Gy, bladder wallD15cm3, penile bulbD5 cm3, penile bulbD3cm3, penile bulbD5cm3, sigmoid colonD20cm3 were achieved compared to the HDG-SCH plans. The magnitude of target coverage improvement was similar in the LDG and HDG groups, although higher prescribed doses were related to increased OAR doses in both SCH and ADP plans, particularly in the HDG group. CONCLUSIONS: CBCT-based online adaptive SBRT for prostate cancer significantly improves target coverage compared to the scheduled plans. Although the benefits of OARs dose vary, adaptive planning offers significant dosimetric advantages, especially at higher prescribed doses. These findings support the integration of oART into prostate SBRT to optimize the treatment's efficacy and safety.
引用
- Gáldi Á, Ágoston P, Pesznyák C, et al. CBCT based online daily adaptive treatment improves target coverage with limited benefit for OAR protection in SBRT prostate cancer. Radiat Oncol. 2026. PMID: 42415083. doi:10.1186/s13014-026-02888-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。